Table 2.

Patient outcomes

Engraftment (n, %)
Yes	143 (88%)
No	20 (12%)
Myeloid chimerism at 2 years (avg)	81.1% (range, 0%-100%)
GVHD (n, %)
acute GVHD	22 (13%)
chronic GVHD	13 (8%)
Number of VOE (average [range], events per 100 patient-years)
All participants (N = 163)
2 y before transplant	5.6 (0-52), 1.7
0-12 mo after transplant	0.8 (0-12), 0.5
12-24 mo after transplant	0.1 (0-8), 0.06
Engrafted participants (N = 143)
2 y before transplant	5.6 (0-52), 1.7
0-12 mo after transplant	0.8 (0-12), 0.5
12-24 mo after transplant	0.03 (0-3), 0.02
Rejected participants (N = 20)
2 y before transplant	6.6 (0-24), 2
0-12 mo after transplant	1.1 (0-6), 0.7
12-24 mo after transplant	0.8 (0-8), 0.5
Participants with GVHD (N = 31)
2 y before transplant	3.5 (0-23), 1.1
0-12 mo after transplant	0.1 (0-1), 0.06
12-24 mo after transplant	0 (0), 0

GVHD, graft-vs-host disease; VOE, vaso-occlusive event.